Jump to content

Covid-19: Razvoj vakcine, imunitet i primena medikamenata


Recommended Posts


Ronapreve: 'Most vulnerable' to get new Covid drug next week


The UK's "most vulnerable" hospital patients, who are unable to build up an antibody response to Covid, will be offered new drug Ronapreve from Monday. 

The new Covid treatment, approved just last month, uses a pair of laboratory-made antibodies to attack the virus.

It was famously used as part of the suite of experimental medicines given to US President Donald Trump last year. 

The antibody cocktail has been shown to reduce hospital stays by four days and cut the risk of death by a fifth.

The government said it had secured sufficient supply of the new therapeutic for eligible NHS patients across the four nations to cover the forthcoming winter.

Health Secretary Sajid Javid said he was "thrilled it will be saving lives from as early as next week".

The new treatment is expensive and priority will be given to those patients at greatest risk of becoming severely ill. 

It will be offered to those over-50 without the necessary antibodies, and those aged 12-49 who are immuno-compromised - for example those with certain cancers - who struggle to mount an antibody response, either through being exposed to Covid, or from vaccination.


Link to comment

A late-stage clinical trial has found a three-dose Chinese vaccine developed by Chongqing Zhifei Biological Products to be nearly 82 percent effective in preventing diseases related to COVID-19 and over 77 percent effective against the highly transmissible Delta variant of the novel coronavirus, the company said last week.

The recombinant protein vaccine uses the spike protein of the virus to trigger immune responses. It is the first and so far the only vaccine approved for emergency use in China to have adopted that technology.

In a statement issued on Friday, the company said a third-stage human trial of the vaccine was launched in December in China, Uzbekistan, Pakistan, Indonesia and Ecuador, enrolling a total of 28,500 people. (...)

It added that the vaccine is 100 percent effective at preventing severe cases and deaths.


Edited by vememah
Link to comment

Nosni sprej koji deluje 6-8 h po uzimanju štiti 63% od zaražavanja. Testiranje je obavljeno na visokorizičnoj populaciji nevakcinisanih zdravstvenih radnika u Indiji u mesecima kad je u toj zemlji bio pik talasa.




Edited by vememah
  • +1 1
Link to comment


Merck said earlier this year that a small, mid-stage trial found that after five days of molnupiravir treatment, none of the patients taking various doses of the drug tested positive for the virus, while 24 per cent of placebo patients had detectable levels of the virus.

Merck is currently conducting two Phase III trials of the antiviral it is developing with Ridgeback Biotherapeutics — one to treat Covid-19 and another to prevent it.

The trial enrolled non-hospitalised Covid-19 patients who have had symptoms for no more than five days and are at risk for severe disease. The Phase III treatment study is expected to finish in early November, Mr Grobler said.



Link to comment

da li ce antivakseri biti i protiv nekog buduceg efikasnog leka, s obzirom na to da ne uzimaju nista sto nije proslo stogodisnji probni period - al opet, cim se pije, ne moz biti toliko opasno ko kad bodu...

doduse, ako sve to bude imalo nekog smisla i bude efikasno, sigurno ce biti protiv,

Link to comment

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...